A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
Open Access
- 1 June 2023
- journal article
- review article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 16, 1709-1720
Abstract
T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and sodium N- (8- [2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates semaglutide absorption across the gastric epithelium in a concentration-dependent manner. This family of drugs apart from glucose lowering effects causes significant weight loss with lower risk of hypoglycemia, and some of them have been linked to a significant reduced major adverse cardiovascular events. GLP-1 RAs may assist persons with T2DM and chronic kidney disease (CKD), a major microvascular consequence of T2DM, in ways other than lowering blood sugar. Several large clinical studies, the bulk of which are cardiovascular outcome trials, show that GLP-1 RA treatment is safe and tolerated for persons with T2DM and impaired renal function and that it may potentially have renoprotective characteristics. This article focuses on the advances of oral GLP1-RA and describes the key milestones and predicted advantages.Keywords
This publication has 70 references indexed in Scilit:
- Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complicationsThe Review of Diabetic Studies, 2012
- Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitusCleveland Clinic Journal of Medicine, 2009
- Depression and heart rate variability in patients with coronary heart diseaseCleveland Clinic Journal of Medicine, 2009
- Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in isletsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- The biology of incretin hormonesCell Metabolism, 2006
- Neural regulation of glucagon-like peptide-1 secretion in pigsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Regulation and organization of adenylyl cyclases and cAMPBiochemical Journal, 2003
- 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic PropertiesJournal of Medicinal Chemistry, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptorEndocrinology, 1993